Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03984448
Title Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

diffuse large B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.